Spring Discovery

Spring Discovery, which rebranded to Spring Science in October 2023, operates a platform leveraging artificial intelligence and machine learning to accelerate therapeutic discovery, with a particular focus on aging-related diseases. Founded in 2017 by Ben Kamens, who previously served as the VP of Engineering at Khan Academy, the company aims to equip scientists with advanced computational tools to analyze complex biological data. The firm's technological approach combines automated lab processes with machine learning to expedite experimentation and uncover new treatments for conditions like cardiovascular and neurodegenerative diseases.

The company's business model encompasses both strategic collaborations and software licensing. It partners with biotech firms, pharmaceutical companies, and academic research groups, acting as an extension of their preclinical discovery efforts. Clients have included organizations such as UCSF, the Bill & Melinda Gates Foundation, and Gilead Sciences. In May 2023, Spring announced a partnership with TetraScience to further integrate AI and machine learning into scientific research and development. The platform's software is designed to help scientists make decisions using high-dimensional data, moving beyond traditional image analysis to identify complex cell behaviors and mine data for insights.

Spring Science's core offering is its AI-powered platform, which includes products like Anvil, Immune Compass, and MegaMap. This technology allows researchers to test thousands of potential treatments and map changes in the immune system, generating strong conviction in screening hits through data-rich assays. The platform has been validated across multiple diseases, demonstrating its broad therapeutic relevance. In a significant development, the company's AI R&D platform was recently acquired by a major Bay Area biotech leader, where it will continue to be used in the pursuit of new therapies. Following this acquisition, Spring Science has indicated a strategic shift from running its own discovery programs to focusing on partnerships and the commercial availability of its imaging platform to the broader scientific community.

Keywords: therapeutic discovery, machine learning, drug discovery, aging research, AI in healthcare, computational biology, preclinical research, biotech partnerships, high-content imaging, phenotypic screening, immune aging, drug development, lab automation, data-rich assays, cell behavior analysis, scientific software, R&D platform, discovery engine, image analysis suite, clinical-stage pipeline